Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Novo Nordisk

Medtide launches IPO

​​Medtide launches IPO to bulk up its weight-loss business

The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks  Key Takeaways: The global market for developing…
June 26, 2025
3880.HK
Will Trump’s drug order derail China’s overseas pharma push?

Will Trump’s drug order put the brakes on China’s overseas pharma drive?

The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
May 22, 2025
Innogen Pharma

Innogen Pharma jostles for a slice of the weight-loss market

The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
December 13, 2024
派格生物減肥藥

PegBio aims to bulk up its finances to deliver weight-loss drugs

The Chinese developer of anti-obesity and diabetes drugs has applied for a Hong Kong listing to fund its commercial plans, but will face strong competition Key Takeaways: The company’s core…
November 21, 2024
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand.

Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs

The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
September 27, 2024
1672.HK
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there.

Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs

The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
August 16, 2024
CSPC Pharma weighs up diet drug for bigger bottom line

CSPC Pharma weighs up diet drug for bigger bottom line

After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business  Key Takeaways: CSPC…
June 5, 2024
1093.HK
Load more

Recent Articles

Medtide launches IPO
June 26, 2025

​​Medtide launches IPO to bulk up its weight-loss business

3880.HK
May 22, 2025

Will Trump’s drug order put the brakes on China’s overseas pharma drive?

December 13, 2024

Innogen Pharma jostles for a slice of the weight-loss market

November 21, 2024

PegBio aims to bulk up its finances to deliver weight-loss drugs

September 27, 2024

Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs

1672.HK
August 16, 2024

Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs

June 5, 2024

CSPC Pharma weighs up diet drug for bigger bottom line

1093.HK

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. May 8, 2025
    RNA drug developer Ribo Life targets fresh funding channel
  3. May 22, 2025
    Will Trump’s drug order put the brakes on China’s overseas pharma drive?
  4. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  5. June 12, 2025
    CSPC Pharma teases big bucks deals after earnings miss
    1093.HK
  6. April 17, 2025
    WuXi group wrestles with uncertainty over pharma tariffs
    2268.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.